{"commentary":{"count":60,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":22,"x_thread":21,"podcast":15,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05678673\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"STELLAR-304","nct_id":"NCT05678673","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stellar-304-nct05678673. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"STELLAR-304","arms":[{"description":"Subjects with advanced or metastatic nccRCC will receive XL092 + nivolumab","label":"XL092 + Nivolumab","type":"EXPERIMENTAL"},{"description":"Subjects with advanced or metastatic nccRCC will receive an active comparator of sunitinib","label":"Sunitinib Malate","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-06-30","type":"ESTIMATED"},"conditions":["Non-Clear Cell Renal Cell Carcinoma"],"enrollment":{"count":317,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"XL092","type":"DRUG"},{"name":"Nivolumab","type":"DRUG"},{"name":"Sunitinib Malate","type":"DRUG"}],"last_update":"2026-07-29","lead_sponsor":"Exelixis","official_title":"A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-12-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Duration of Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), by Blinded Independent Radiology Committee (BIRC)","timeFrame":"Approximately 27 months after the first subject is randomized"},{"measure":"Objective response rate (ORR) as assessed by BIRC per RECIST 1.1","timeFrame":"Up to 24 months after the first subject is randomized"}],"references":[{"citation":"Pal SK, Powles T, Kanesvaran R, Molina-Cerrillo J, Feldman DR, Barata P, Liu M, Bhatt A, Wang Z, Nandoskar P, Suarez C. STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma. Future Oncol. 2025 Mar;21(7):787-794. doi: 10.1080/14796694.2025.2458395. Epub 2025 Feb 26.","pmid":"40008409","type":"DERIVED"}],"start_date":{"date":"2023-01-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT05678673"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stellar-304-nct05678673"}